TY  - JOUR
AU  - Simoes, Catia
AU  - Paiva, Bruno
AU  - Martinez-Cuadron, David
AU  - Bergua, Juan-Miguel
AU  - Vives, Susana
AU  - Algarra, Lorenzo
AU  - Tormo, Mar
AU  - Martinez, Pilar
AU  - Serrano, Josefina
AU  - Herrera, Pilar
AU  - Ramos, Fernando
AU  - Salamero, Olga
AU  - Lavilla, Esperanza
AU  - Gil, Cristina
AU  - Lopez, Jose-Luis
AU  - Vidriales, Maria-Belen
AU  - Labrador, Jorge
AU  - Falantes, Jose-Francisco
AU  - Sayas, María-Jose
AU  - Ayala, Rosa
AU  - Martinez-Lopez, Joaquin
AU  - Villar, Sara
AU  - Calasanz, Maria-Jose
AU  - Prosper, Felipe
AU  - San-Miguel, Jesus F
AU  - Sanz, Miguel Angel
AU  - Montesinos, Pau
PY  - 2021
DO  - 10.1182/bloodadvances.2020003195
UR  - http://hdl.handle.net/10668/17127
T2  - Blood advances
AB  - The value of measurable residual disease (MRD) in elderly patients with acute myeloid leukemia (AML) is inconsistent between those treated with intensive vs hypomethylating drugs, and unknown after semi-intensive therapy. We investigated the role of...
LA  - en
PB  - American Society of Hematology
KW  - Aged
KW  - Cytarabine
KW  - Humans
KW  - Leukemia, myeloid, acute
KW  - Neoplasm, residual
KW  - Prognosis
KW  - Remission induction
TI  - Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
TY  - Research article
VL  - 5
ER  -